3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients.

IJTLD open Pub Date : 2024-09-01 DOI:10.5588/ijtldopen.24.0305

A Kinikar, R Borse, B Randive, P Kamath, S K Mattoo, M Parmar, H Solanki, V Mave, A Gupta, R E Chaisson, N Suryavanshi

{"title":"3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients.","authors":"A Kinikar, R Borse, B Randive, P Kamath, S K Mattoo, M Parmar, H Solanki, V Mave, A Gupta, R E Chaisson, N Suryavanshi","doi":"10.5588/ijtldopen.24.0305","DOIUrl":null,"url":null,"abstract":"Introduction: India's National TB Elimination Programme plans to roll out short-course TB preventive therapy (TPT) using 3 months of rifapentine and isoniazid (3HP). Understanding the feasibility and safety of children in programmatic settings is critical for widespread implementation. We present the findings of a targeted scale-up of 3HP among children and adolescents living with HIV (CALHIV) and child household contacts (>2 to <6 years) of pulmonary TB patients (CHHC).Methods: Between December 2021 and July 2023, eligible CALHIV and CHHC participants were given weekly dosages of 3HP for 3 months at antiretroviral therapy (ART) and TB clinics, respectively, of a public hospital in Pune, India.Results: Of 97 children screened, 91 initiated 3HP (32 CALHIV and 59 CHHC). The median age of CALHIV was 14 years; 66% were male and on dolutegravir-based ART. The median age of CHHC was 4 years; 47% were males. Thirty-one (97%) CALHIV and 56 (95%) CHHC completed 3HP without dolutegravir dose adjustment. None of the child participants discontinued 3HP due to adverse events. No child participant developed TB during 1 year of follow-up post-3HP.Conclusion: Our study provides evidence of the uptake and feasibility of the planned nationwide rollout of 3HP.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 9","pages":"413-417"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409175/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJTLD open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/ijtldopen.24.0305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: India's National TB Elimination Programme plans to roll out short-course TB preventive therapy (TPT) using 3 months of rifapentine and isoniazid (3HP). Understanding the feasibility and safety of children in programmatic settings is critical for widespread implementation. We present the findings of a targeted scale-up of 3HP among children and adolescents living with HIV (CALHIV) and child household contacts (>2 to <6 years) of pulmonary TB patients (CHHC).

Methods: Between December 2021 and July 2023, eligible CALHIV and CHHC participants were given weekly dosages of 3HP for 3 months at antiretroviral therapy (ART) and TB clinics, respectively, of a public hospital in Pune, India.

Results: Of 97 children screened, 91 initiated 3HP (32 CALHIV and 59 CHHC). The median age of CALHIV was 14 years; 66% were male and on dolutegravir-based ART. The median age of CHHC was 4 years; 47% were males. Thirty-one (97%) CALHIV and 56 (95%) CHHC completed 3HP without dolutegravir dose adjustment. None of the child participants discontinued 3HP due to adverse events. No child participant developed TB during 1 year of follow-up post-3HP.

Conclusion: Our study provides evidence of the uptake and feasibility of the planned nationwide rollout of 3HP.

查看原文本刊更多论文

对感染艾滋病毒的儿童和青少年以及与结核病患者有家庭接触的儿童进行 3HP 预防性治疗。

导言：印度国家消除结核病计划（National TB Elimination Programme）计划推广使用利福喷丁和异烟肼（3HP）治疗 3 个月的短期结核病预防疗法（TPT）。了解儿童在计划环境中的可行性和安全性对于广泛实施至关重要。我们介绍了在感染艾滋病病毒的儿童和青少年（CALHIV）以及儿童家庭接触者（大于 2 岁）中有针对性地推广 3HP 的研究结果：2021 年 12 月至 2023 年 7 月期间，印度浦那一家公立医院的抗逆转录病毒疗法（ART）诊所和结核病诊所分别为符合条件的 CALHIV 和 CHHC 参与者提供了为期 3 个月的 3HP 每周剂量：在接受筛查的 97 名儿童中，91 人开始服用 3HP（32 名 CALHIV 和 59 名 CHHC）。CALHIV 的中位年龄为 14 岁；66% 为男性，正在接受基于多罗替拉韦的抗逆转录病毒疗法。CHHC 的中位年龄为 4 岁；47% 为男性。31名（97%）CALHIV和56名（95%）CHHC完成了3HP，没有进行多鲁特韦剂量调整。没有一名儿童参与者因不良反应而中断 3HP 的治疗。在 3HP 后 1 年的随访期间，没有儿童参与者患上结核病：我们的研究为计划在全国范围内推广 3HP 的接受度和可行性提供了证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

IJTLD open

自引率

0.00%

发文量